Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3
I. Borget, J. Cadranel, J-P. Pignon, E. Quoix, B. Coudert, V. Westeel, E. Dansin, J. Madelaine, A. Madroszyk, S. Friard, C. Daniel, F. Morin, C. Chouaid, the ERMETIC Collaborative Group
European Respiratory Journal Jan 2012, 39 (1) 172-179; DOI: 10.1183/09031936.00201210